Ena Therapeutics

Developing TLR2 angonist for the prevention of respiratory infections in the patients with preexisting lung diseases

placeMelbourne, Victoria, Australia calendar_todayFounded 2014 language enatherapeutics.com

Innovation

7 patent families (1 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 405 times.

YearFilings
20181
20194
20205
20216
20221

Investor mix

3 investors on record.

Investor typeCountShare
Venture capital3100%
Coming soon